Quarterly report [Sections 13 or 15(d)]

Fair Value of Financial Instruments - Narrative (Details)

v3.25.1
Fair Value of Financial Instruments - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Feb. 25, 2025
Dec. 31, 2024
Sep. 30, 2021
Subsidiary, Sale of Stock [Line Items]          
Changes in fair value $ (13,634)        
Fair value, asset, recurring basis, unobservable input reconciliation, gain (loss), statement of income or comprehensive income Other Nonoperating Income (Expense) Other Nonoperating Income (Expense)      
Fair value, liability, recurring basis, unobservable input reconciliation, gain (loss), statement of income or comprehensive income Other Nonoperating Income (Expense) Other Nonoperating Income (Expense)      
Common Stock          
Subsidiary, Sale of Stock [Line Items]          
Common issued for warrants exercised (in shares) 9,499,138        
Private Warrants          
Subsidiary, Sale of Stock [Line Items]          
Warrants outstanding (in shares) 2,633,195   5,098,978 7,732,168 7,732,168
Number of warrants to purchase common stock (in shares)         1
Fair value (in dollars per share) $ 2.54   $ 6.84 $ 7.15  
Changes in fair value $ (13,600) $ 1,100      
Proceeds from warrant exercises $ 5,400        
Class of warrants exercised (in shares) 4,631,799        
Warrants exercised (in shares) 467,174        
Private Warrants | Common Stock          
Subsidiary, Sale of Stock [Line Items]          
Common issued for warrants exercised (in shares) 2,293,739        
Warrants exercised (in shares) 467,174        
Public Warrants          
Subsidiary, Sale of Stock [Line Items]          
Warrants outstanding (in shares) 0     8,188,811  
Number of warrants to purchase common stock (in shares) 1        
Fair value (in dollars per share) $ 11.50       $ 11.50
Proceeds from warrant exercises $ 77,500